Anti-inflammatory therapy in type 1 diabetes

Current Diabetes Reports

Volumn 12, Issue 5, 2012, Pages 499-509

  Baumann, Bernd ^a   Salem, Heba H ^a,b   Boehm, Bernhard O ^a  

^a UNIVERSITY OF ULM   (Germany)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

cell death; Anti inflammatory therapy; Combination therapy; Inflammation; Insulitis; NF B; NOD mice; Type 1 diabetes

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ACETYLSALICYLIC ACID; ALPHA 1 ANTITRYPSIN; ATORVASTATIN; C REACTIVE PROTEIN; CANAKINUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 2; RILONACEPT; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DISEASE MODEL; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNITY; CLINICAL TRIALS AS TOPIC; CYTOKINES; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN-SECRETING CELLS; MODELS, BIOLOGICAL; NF-KAPPA B;

EID: 84870850148     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0299-y     Document Type: Article

References (100)

1. Mordes JP, Bortell R, Doukas J, Rigby M, Whalen B, et al. The BB/Wor rat and the balance hypothesis of autoimmunity. Diabetes Metab Rev. 1996;12:103-9. (Pubitemid 26280009)
2. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol. 2005;23:447-85. (Pubitemid 40563177)
3. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol. 2009;155:173-81.
4. Dotta F, Censini S, van Halteren AG, Marselli L, Masini M, et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A. 2007;104:5115-20. (Pubitemid 47186185)
5. Uno S, Imagawa A, Okita K, Sayama K, Moriwaki M, et al. Macrophages and dendritic cells infiltrating islets with or without beta cells produce tumor necrosis factor-alpha in patients with recent-onset type 1 diabetes. Diabetologia. 2007;50:596-601. (Pubitemid 46215503)
6. Coppieters KT, Dotta F, Amirian N, Campbell PD, Kay TW, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med. 2012;209:51-60.
7. Richardson SJ, Willcox A, Bone AJ, Morgan NG, Foulis AK. Immunopathology of the human pancreas in type-I diabetes. Semin Immunopathol. 2011;33:9-21.
8. Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science. 2009;324:387-9.
9. Eizirik DL, Sammeth M, Bouckenooghe T, Bottu G, Sisino G, et al. The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of proinflammatory cytokines. PLoS Genet. 2012;8:e1002552.
10. Sarkar SA, Lee CE, Victorino F, Nguyen TT, Walters JA, et al. Expression and regulation of chemokines in murine and human type 1 diabetes. Diabetes. 2012;61:436-46.
11. Fairfax BP, Makino S, Radhakrishnan J, Plant K, Leslie S, et al. Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles. Nat Genet. 2012;44:502-10.
12. Tersey SA, Nishiki Y, Templin AT, Cabrera SM, Stull ND, et al. Islet beta-cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the non-obese diabetic mouse model. Diabetes. 2012;61:818-27.
13. Baker RG, Hayden MS, Ghosh S. NF-κB, inflammation, and metabolic disease. Cell Metab. 2011;13:11-22.
14. Karin M. The IκB kinase - a bridge between inflammation and cancer. Cell Res. 2008;18:334-42.
15. Scheidereit C. IκB kinase complexes: gateways to NF-κB activation and transcription. Oncogene. 2006;25:6685-705. (Pubitemid 44657846)
16. Polychronakos C, Li Q. Understanding type 1 diabetes through genetics: advances and prospects. Nat Rev Genet. 2011;12:781-92.
17. Hegazy DM, O'Reilly DA, Yang BM, Hodgkinson AD, Millward BA, et al. NFκB polymorphisms and susceptibility to type 1 diabetes. Genes Immun. 2001;2:304-8. (Pubitemid 33674241)
18. Berchtold LA, Storling ZM, Ortis F, Lage K, Bang-Berthelsen C, et al. Huntingtin-interacting protein 14 is a type 1 diabetes candidate protein regulating insulin secretion and beta-cell apoptosis. Proc Natl Acad Sci U S A. 2011;108:E681-8.
19. Katarina K, Daniela P, Peter N, Marianna R, Pavlina C, et al. HLA, NFκB1, and NFKBIA gene polymorphism profile in autoimmune diabetes mellitus patients. Exp Clin Endocrinol Diabetes. 2007;115:124-9. (Pubitemid 46408121)
20. Guo D, Li M, Zhang Y, Yang P, Eckenrode S, et al. A functional variant of SUMO4, a new IκB alpha modifier, is associated with type 1 diabetes. Nat Genet. 2004;36:837-41. (Pubitemid 39014100)
21. Ouaaz F, Arron J, Zheng Y, Choi Y, Beg AA. Dendritic cell development and survival require distinct NF-κB subunits. Immunity. 2002;16:257-70. (Pubitemid 34211965)
22. Martin E, O'Sullivan B, Low P. Thomas R Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity. 2003;18:155-67. (Pubitemid 36120696)
23. Moore F, Buonocore S, Aksoy E, Ouled-Haddou N, Goriely S, et al. An alternative pathway of NF-κB activation results in maturation and T cell priming activity of dendritic cells overexpressing a mutated IκBα. J Immunol. 2007;178:1301-11. (Pubitemid 46154600)
24. Lamhamedi-Cherradi SE, Zheng S, Hilliard BA, Xu L, Sun J, et al. Transcriptional regulation of type I diabetes by NF-κ B. J Immunol. 2003;171:4886-92.
25. Mabley JG, Hasko G, Liaudet L, Soriano FG, Southan GJ, et al. NFκB1 (p50)-deficient mice are not susceptible to multiple lowdose streptozotocin-induced diabetes. J Endocrinol. 2002;173:457-64. (Pubitemid 34704717)
26. Weaver Jr DJ, Poligone B, Bui T, Abdel-Motal UM, Baldwin Jr AS, et al. Dendritic cells from nonobese diabetic mice exhibit a defect in NF-κB regulation due to a hyperactive IκB kinase. J Immunol. 2001;167:1461-8. (Pubitemid 32703145)
27. Poligone B,Weaver Jr DJ, Sen P, Baldwin Jr AS, Tisch R. Elevated NF-κB activation in non-obese diabetic mouse dendritic cells results in enhanced APC function. J Immunol. 2002;168:188-96. (Pubitemid 34014118)
28. Wheat W, Kupfer R, Gutches DG, Rayat GR, Beilke J, et al. Increased NF-κ B activity in B cells and bone marrow-derived dendritic cells from NOD mice. Eur J Immunol. 2004;34:1395-404. (Pubitemid 39256019)
29. Katz JD, Benoist C, Mathis D. T helper cell subsets in insul-independent diabetes. Science. 1995;268:1185-8.
30. Boothby MR, Mora AL, Scherer DC, Brockman JA, Ballard DW. Perturbation of the T lymphocyte lineage in transgenic mice expressing a constitutive repressor of nuclear factor (NF)-κB. J Exp Med. 1997;185:1897-907. (Pubitemid 27247076)
31. Wan YY, DeGregori J. The survival of antigen-stimulated T cells requires NFκB-mediated inhibition of p73 expression. Immunity. 2003;18:331-42. (Pubitemid 36355940)
32. Dale E, Davis M, Faustman DL. A role for transcription factor NF-κB in autoimmunity: possible interactions of genes, sex, and the immune response. Adv Physiol Educ. 2006;30:152-8. (Pubitemid 44749373)
33. Schreck R, Baeuerle PA. NF-κ B as inducible transcriptional activator of the granulocyte-macrophage colony-stimulating factor gene. Mol Cell Biol. 1990;10:1281-6.
34. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-κB/Rel in induction of nitric oxide synthase. J Biol Chem. 1994;269:4705-8. (Pubitemid 24239438)
35. Sen P, Bhattacharyya S, Wallet M, Wong CP, Poligone B, et al. NF-κ B hyperactivation has differential effects on the APC function of non-obese diabetic mouse macrophages. J Immunol. 2003;170:1770-80. (Pubitemid 36197392)
36. Liou HC, Hsia CY. Distinctions between c-Rel and other NF-κB proteins in immunity and disease. Bioessays. 2003;25:767-80. (Pubitemid 36966377)
37. Kaileh M, Sen R. NF-κB function in B lymphocytes. Immunol Rev. 2012;246:254-71.
38. Marino E, Silveira PA, Stolp J, Grey ST. B cell-directed therapies in type 1 diabetes. Trends Immunol. 2011;32:287-94.
39. Rahman A, Fazal F. Blocking NF-κB: an inflammatory issue. Proc Am Thorac Soc. 2012;8:497-503.
40. Gerondakis S, Grumont R, Gugasyan R,Wong L, Isomura I, et al. Unraveling the complexities of the NF-κB signaling pathway using mouse knockout and transgenic models. Oncogene. 2006;25:6781-99. (Pubitemid 44657852)
41. Vlantis K, Pasparakis M. Role of TNF in pathologies induced by nuclear factor κB deficiency. Curr Dir Autoimmun. 2010;11:80-93.
42. Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of treg-mediated T cell suppression. Front Immunol. 2012;3:51.
43. Patel S, Santani D. Role of NF-κ B in the pathogenesis of diabetes and its associated complications. Pharmacol Rep. 2009;61:595-603.
44. Zhao Y, Krishnamurthy B, Mollah ZU, Kay TW, Thomas HE. NF-κB in type 1 diabetes. Inflamm Allergy Drug Targets. 2011;10:208-17.
45. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, et al. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005;54 Suppl 2: S97-107. (Pubitemid 43343337)
46. Eizirik DL, Mandrup-Poulsen T. A choice of death - the signaltransduction of immune-mediated beta-cell apoptosis. Diabetologia. 2001;44:2115-33. (Pubitemid 34015464)
47. Cardozo AK, Heimberg H, Heremans Y, Leeman R, Kutlu B, et al. A comprehensive analysis of cytokine-induced and nuclear factor-κ B-dependent genes in primary rat pancreatic beta cells. J Biol Chem. 2001;276:48879-86.
48. Giannoukakis N, Rudert WA, Trucco M, Robbins PD. Protection of human islets from the effects of interleukin-1beta by adenoviral gene transfer of an IκB repressor. J Biol Chem. 2000;275:36509-13. (Pubitemid 32002047)
49. Heimberg H, Heremans Y, Jobin C, Leemans R, Cardozo AK, et al. Inhibition of cytokine-induced NF-κB activation by adenovirus-mediated expression of a NF-κB super-repressor prevents beta-cell apoptosis. Diabetes. 2001;50:2219-24. (Pubitemid 33641904)
50. Chang I, Kim S, Kim JY, Cho N, Kim YH, et al. Nuclear factor κB protects pancreatic beta cells from tumor necrosis factor-α-mediated apoptosis. Diabetes. 2003;52:1169-75. (Pubitemid 36523352)
51. Thomas HE, Angstetra E, Fernandes RV, Mariana L, Irawaty W, et al. Perturbations in nuclear factor-κB or c-Jun N-terminal kinase pathways in pancreatic beta cells confer susceptibility to cytokine-induced cell death. Immunol Cell Biol. 2006;84:20-7.
52. Kim S, Millet I, Kim HS, Kim JY, Han MS, et al. NF-κB prevents beta-cell death and autoimmune diabetes in NOD mice. Proc Natl Acad Sci U S A. 2007;104:1913-8. (Pubitemid 46239878)
53. Cardozo AK, Proost P, Gysemans C, Chen MC, Mathieu C, et al. IL-1beta and IFN-gamma induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice. Diabetologia. 2003;46:255-66. (Pubitemid 36343890)
54. Kutlu B, Darville MI, Cardozo AK, Eizirik DL. Molecular regulation of monocyte chemoattractant protein-1 expression in pancreatic beta cells. Diabetes. 2003;52:348-55. (Pubitemid 36173189)
55. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res. 2001;50:537-46. (Pubitemid 34087272)
56. Herold KC, Vezys V, Sun Q, Viktora D, Seung E, et al. Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol. 1996;156:3521-7. (Pubitemid 26123569)
57. Muller A, Schott-Ohly P, Dohle C, Gleichmann H. Differential regulation of Th1-type and Th2-type cytokine profiles in pancreatic islets of C57BL/6 and BALB/c mice by multiple low doses of streptozotocin. Immunobiology. 2002;205:35-50. (Pubitemid 34285406)
58. Manikandan R, Thiagarajan R, Beulaja S, Sivakumar MR, Meiyalagan V, et al. 1, 2 di-substituted idopyranose from Vitex negundo l. Protects against streptozotocin-induced diabetes by inhibiting nuclear factor-κB and inducible nitric oxide synthase expression. Microsc Res Tech. 2011;74:301-7.
59. Song MY, Jeong GS, Kwon KB, Ka SO, Jang HY, et al. Sulfuretin protects against cytokine-induced beta-cell damage and prevents streptozotocin-induced diabetes. Exp Mol Med. 2010;42:628-38.
60. Kwon KB, Kim EK, Jeong ES, Lee YH, Lee YR, et al. Cortex cinnamomi extract prevents streptozotocin-and cytokine-induced beta-cell damage by inhibiting NF-κB. World J Gastroenterol. 2006;12:4331-7.
61. Yuan HD, Chung SH. Fermented ginseng protects streptozotocininduced damage in rat pancreas by inhibiting nuclear factor-κB. Phytother Res. 2010;24 Suppl 2:S190-5.
62. Saha SS, Ghosh M. Antioxidant and anti-inflammatory effect of conjugated linolenic acid isomers against streptozotocin-induced diabetes. Br J Nutr. 2011. doi:10.1017/S0007114511006325.
63. Hu CM, Li JS, Cheah KP, Lin CW, Yu WY, et al. Effect of Sanguis draconis (a dragon's blood resin) on streptozotocinand cytokine-induced beta-cell damage, in vitro and in vivo. Diabetes Res Clin Pract. 2011;94:417-25.
64. Ueberberg S, Deutschbein T, Klein HH, Dietrich JW, Akinturk S, et al. Protection from diabetes development by single-chain antibody-mediated delivery of a NF-κB inhibitor specifically to beta-cells in vivo. Am J Physiol Endocrinol Metab. 2011;301: E83-90.
65. Eldor R, Yeffet A, Baum K, Doviner V, Amar D, et al. Conditional and specific NF-κB blockade protects pancreatic beta cells from diabetogenic agents. Proc Natl Acad Sci U S A. 2006;103:5072-7.
66. Schott-Ohly P, Lgssiar A, Partke HJ, Hassan M, Friesen N, et al. Prevention of spontaneous and experimentally induced diabetes in mice with zinc sulfate-enriched drinking water is associated with activation and reduction of NF-κ B and AP-1 in islets, respectively. Exp Biol Med (Maywood). 2004;229:1177-85. (Pubitemid 39602261)
67. Bellenger J, Bellenger S, Bataille A, Massey KA, Nicolaou A, et al. High pancreatic n-3 fatty acids prevent STZ-induced diabetes in fat-1 mice: inflammatory pathway inhibition. Diabetes. 2011;60:1090-9.
68. Norlin S, Ahlgren U, Edlund H. Nuclear factor-κB activity in beta-cells is required for glucose-stimulated insulin secretion. Diabetes. 2005;54:125-32. (Pubitemid 40105103)
69. Koulmanda M, Budo E, Bonner-Weir S, Qipo A, Putheti P, et al. Modification of adverse inflammation is required to cure newonset type 1 diabetic hosts. Proc Natl Acad Sci U S A. 2007;104:13074-9. (Pubitemid 351737595)
70. Thomas HE, Irawaty W, Darwiche R, Brodnicki TC, Santamaria P, et al. IL-1 receptor deficiency slows progression to diabetes in the NOD mouse. Diabetes. 2004;53:113-21. (Pubitemid 38044705)
71. Lee SM, Yang H, Tartar DM, Gao B, Luo X, et al. Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. Diabetologia. 2011;54:1136-46.
72. Gonzalez R, Ballester I, Lopez-Posadas R, Suarez MD, Zarzuelo A, et al. Effects of flavonoids and other polyphenols on inflammation. Crit Rev Food Sci Nutr. 2012;51:331-62.
73. Maier B, Ogihara T, Trace AP, Tersey SA, Robbins RD, et al. The unique hypusine modification of eIF5A promotes islet betacell inflammation and dysfunction in mice. J Clin Invest. 2010;120:2156-70.
74. Ruan Q, Wang T, Kameswaran V, Wei Q, Johnson DS, et al. The microRNA-21-PDCD4 axis prevents type 1 diabetes by blocking pancreatic beta-cell death. Proc Natl Acad Sci U S A. 2011;108:12030-5.
75. Lipton R, LaPorte RE, Becker DJ, Dorman JS, Orchard TJ, et al. Cyclosporin therapy for prevention and cure of IDDM. Epidemiological perspective of benefits and risks. Diabetes Care. 1990;13:776-84. (Pubitemid 20207427)
76. Blonska M, Lin X. NF-κB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res. 2011;21:55-70.
77. Thome M, Charton JE, Pelzer C, Hailfinger S. Antigen receptor signaling to NF-κB via CARMA1, BCL10, and MALT1. Cold Spring Harb Perspect Biol. 2010;2:a003004.
78. Palkowitsch L,Marienfeld U, Brunner C, Eitelhuber A, Krappmann D, et al. The Ca2+-dependent phosphatase calcineurin controls the formation of the Carma1-Bcl10-Malt1 complex during T cell receptor-induced NF-κB activation. J Biol Chem. 2011;286:7522-34.
79. von Noorden C, Die Zuckerkrankheit und ihre Behandlung. In: Hirschwald A, editor. Behandlung mit Arzneimitteln. 5. edition ed. 1910;258-67.
80. Collet JP, Allali Y, Lesty C, Tanguy ML, Silvain J, et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol. 2006;26:2567-73. (Pubitemid 44607482)
81. Tehrani S, Mobarrez F, Antovic A, Santesson P, Lins PE, et al. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thromb Res. 2010;126:e225-31.
82. Tehrani S, Antovic A, Mobarrez F, Mageed K, Lins PE, et al. High-dose aspirin is required to influence plasma fibrin network structure in patients with type 1 diabetes. Diabetes Care. 2012;35:404-8.
83. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(κ)B kinase-beta. Nature. 1998;396:77-80. (Pubitemid 28520452)
84. Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and Aspirin. Science. 1994;265:956-9.
85. Kanda H, Yokota K, Kohno C, Sawada T, Sato K, et al. Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios. Mod Rheumatol. 2007;17:364-8. (Pubitemid 47593482)
86. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet. 2004;363:2015-21. (Pubitemid 38781100)
87. Tang TT, Song Y, Ding YJ, Liao YH, Yu X, et al. Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J Lipid Res. 2011;52:1023-32.
88. Martin S, Herder C, Schloot NC, Koenig W, Heise T, et al. Residual beta-cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial. PLoS One. 2011;6:e17554.
89. Strom A, Kolb H, Martin S, Herder C, Simon MC, et al. Improved preservation of residual beta-cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial). PLoS One. 2012;7:e33108.
90. Beyan H, Riese H, Hawa MI, Beretta G, Davidson HW, et al. Glycotoxin and autoantibodies are additive environmentally determined predictors of type 1 diabetes: a twin and population study. Diabetes. 2012;61:1192-8.
91. Fleming TH, Humpert PM, Nawroth PP, Bierhaus A. Reactive metabolites and AGE/RAGE-mediated cellular dysfunction affect the aging process: a mini-review. Gerontology. 2011;57:435-43.
92. Clynes R, Moser B, Yan SF, Ramasamy R, Herold K, et al. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr Mol Med. 2007;7:743-51.
93. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia. 2009;52:2251-63.
94. Vlassara H, Striker G. Glycotoxins in the diet promote diabetes and diabetic complications. Curr Diab Rep. 2007;7:235-41. (Pubitemid 46951921)
95. Peppa M, He C, Hattori M, McEvoy R, Zheng F, et al. Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes. 2003;52:1441-8. (Pubitemid 36666199)
96. Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci. 2007;62:427-33. (Pubitemid 47065712)
97. Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, et al. The role of oxidative stress and NF-κB activation in late diabetic complications. Biofactors. 1999;10:157-67. (Pubitemid 29533824)
98. Goraca A, Huk-Kolega H, Piechota A, Kleniewska P, Ciejka E, et al. Lipoic acid -biological activity and therapeutic potential. Pharmacol Rep. 2011;63:849-58.
99. Forbes JM, Soderlund J, Yap FY, Knip M, Andrikopoulos S, et al. Receptor for advanced glycation end-products (RAGE) provides a link between genetic susceptibility and environmental factors in type 1 diabetes. Diabetologia. 2012;54:1032-42.
100. Mandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol. 2010;6:158-66.